EMA Recommends 39 Drugs in First Half of 2014 - - BioPharm International

ADVERTISEMENT

EMA Recommends 39 Drugs in First Half of 2014


Thirty-nine drugs were recommended for marketing authorization by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in the first half of 2014, compared with 44 in first half of 2013 and 33 in first half of 2012. The recommended drugs included drugs designed to fill unmet medical needs, treat diseases for which no treatments were previously available, or bring significant added benefit to patients over existing therapies. The number of new medicines intended for the treatment of rare diseases increased, with eight drugs recommended for the treatment of rare diseases in the first half of 2014. The number of drug products recommended for approval via the European Union centralized procedure based on generic or informed consent applications, however, has decreased compared with the first half of 2013 (6 versus 13). 

More than two in three applicants received scientific advice from the CHMP during the development phase, and for innovative medicines, four in five applicants received such advice, a significant increase compared with the first half of 2013. This trend is in line with the growing number of requests for scientific advice received by EMA.

Source: European Medicines Agency

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines

Click here